3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
5
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Hepatocellular
9
Papillomavirus Infections
4
Lymphoma, Non-Hodgkin
4
Hypertension, Portal
4
Febrile Neutropenia
4
Carcinoma, Non-Small-Cell Lung
4
Polycystic Ovary Syndrome
3
Ovarian Cysts
3
Multiple Myeloma
3
Lung Neoplasms
3
Cancer Pain
3
Adenomatous Polyposis Coli
3
Recurrence
2
Rectal Neoplasms
2
Prostatic Hyperplasia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pain
2
Neoplasms
2
Lymphoma, B-Cell
2
Lymphoma
2
Liver Cirrhosis
2
Leiomyoma
2
Infertility
2
Hyperthermia
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Vomiting
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Surgical Wound Infection
1
Interventions
dolutegravir
1
Ritonavir
1
Nucleosides
1
Darunavir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
OTHER_GOV
×
Acquired Immunodeficiency Syndrome
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn